Literature DB >> 8095138

Accumulation of degradation products of doxorubicin and pirarubicin formed in cell culture medium within sensitive and resistant cells.

M Fiallo1, A Laigle, M N Borrel, A Garnier-Suillerot.   

Abstract

Quantitative study of doxorubicin (Adriamycin), pirarubicin (4'-o-tetrahypyranyladriamycin) and daunorubicin in the nucleus of living cells was performed using microspectrofluorometry. As for the cytotoxic assays, drug-sensitive and drug-resistant K562 cells were incubated for 3 days with concentrations of drug ranging from 4 nM to 1 mM. When drug-sensitive cells were incubated with pirarubicin, the spectrum recorded from inside the nucleus was characteristic of anthracycline intercalated between the base pairs in the nucleus. However, when drug-sensitive cells were incubated with doxorubicin and drug-resistant cells with pirarubicin or doxorubicin, a new fluorescent spectrum was obtained which was due to 7,8-dehydro-9,10-desacetyldoxorubicinone, a pirarubicin and doxorubicin degradation product that is formed in the medium. This compound which is highly lipophilic is taken up rapidly into both sensitive and resistant cells.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8095138     DOI: 10.1016/0006-2952(93)90140-r

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  4 in total

1.  Targeting of multidrug-resistant human ovarian carcinoma cells with anti-P-glycoprotein antibody conjugates.

Authors:  Kirk D Fowers; Jindřich Kopeček
Journal:  Macromol Biosci       Date:  2012-01-25       Impact factor: 4.979

2.  Multiscale and Translational Quantitative Systems Toxicology, Pharmacokinetic-Toxicodynamic Modeling Analysis for Assessment of Doxorubicin-Induced Cardiotoxicity.

Authors:  Tanaya R Vaidya; Hardik Mody; Yesenia L Franco; Ashley Brown; Sihem Ait-Oudhia
Journal:  AAPS J       Date:  2021-01-06       Impact factor: 4.009

3.  A Flow Cytometric Clonogenic Assay Reveals the Single-Cell Potency of Doxorubicin.

Authors:  Katie F Maass; Chethana Kulkarni; Mohiuddin A Quadir; Paula T Hammond; Alison M Betts; Karl Dane Wittrup
Journal:  J Pharm Sci       Date:  2015-09-07       Impact factor: 3.534

4.  Tumor targeting with pH-responsive poly(2-oxazoline)-based nanogels for metronomic doxorubicin treatment.

Authors:  Doerte Hoelzer; Meike N Leiske; Matthias Hartlieb; Tanja Bus; David Pretzel; Stephanie Hoeppener; Kristian Kempe; René Thierbach; Ulrich S Schubert
Journal:  Oncotarget       Date:  2018-04-27
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.